Sign inJoin waitlistJoin the waitlist

LG

Lori Goldstein

Physician · TEMPLE FACULTY ANESTHESIOLOGY ASSOCIATES

Credentials: · ·

History

TEMPLE FACULTY ANESTHESIOLOGY ASSOCIATES
Present

Medical Oncology
1985–1987
Internal Medicine
1982–1985
Doctor of Medicine
1978–1982

Research

Expression of a multidrug resistance gene in human cancers
Journal of the National Cancer Institute · 1989 · First of over 10 authors · 1,341 citations
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
Journal of Clinical Oncology · 2014 · 1,031 citations
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast…
Journal of Clinical Oncology · 2003 · 931 citations

Harold Burstein
24 papers
William Gradishar
24 papers
Joseph Sparano
22 papers
LP
Lori Pierce
20 papers
CH
Clifford Hudis
18 papers
DH
Daniel Hayes
17 papers
Benjamin Anderson
16 papers
BM
Beryl McCormick
16 papers
AW
Antonio Wolff
15 papers
ES
Elin Sigurdson
15 papers
Elizabeth Reed
15 papers
Gary Freedman
15 papers · 6 as a resident

Grants

Eastern Cooperative Oncology Group
National Cancer Institute · U10
Contact PI · $4.9M · Research Inst of Fox Chase Can Ctr
1979–2016
Development of Breast Cancer Research Program at Fccc
National Cancer Institute · R21
Contact PI · $329.9K · Fox Chase Cancer Center
1994–1997
Development of Breast Cancer Research Program at Fccc
National Cancer Institute · P20
Contact PI · $329.9K · Fox Chase Cancer Center
1994–1995
Breast, Prostate, Ovarian and Cervical Cancer
National Cancer Institute · R55
Contact PI · $100K · Fox Chase Cancer Center
1993–1995

Clinical trials

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
Principal investigator · Completed · Phase 2
Dompé Farmaceutici S.p.A
2015–2020
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
Principal investigator · Terminated · Phase 2
Dompé Farmaceutici S.p.A
2013–2016
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Principal investigator · Completed · Phase 1
Dompé Farmaceutici S.p.A
2012–2015
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Principal investigator · Completed
Fox Chase Cancer Center
2011–2015